| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2017: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2016: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2015: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Outline of Final Research Achievements |
Induced pluripotent stem cells (iPSCs) hold great promise for regenerative medicine and in vitro modeling of human diseases. To overcome their abnormal differentiation and tumorigenicity, the method to evaluate bona fide “appropriately reprogrammed human iPSCs” has been expected. In this study, by focusing on the differences of the tumorigeniticy (glioma-like tumor formation) among human iPSC clones caused by the incomplete reprogramming and genomic instability, we identified reprogramming recalcitrant genes as “Score card”, and examined their applicability to the evaluation of human iPSCs.
|
